Sign in
Taking people in ItalyPhase 3

Tests a PET scan to find heart amyloidosis without a biopsy

Tests a scan with a tracer to detect heart amyloidosis in adults.

Key facts

Who runs it
Fondazione Toscana Gabriele Monasterio
Where
Bergamo, Ferrara, Naples, Pavia, Pisa, and Trieste, ItalySee the 6 sites
Registry title
A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) to non-invasively diagnose cardiac AL amyloidosis: the PETAL study.
Status
Recruiting
Phase
Phase 3
People taking part
150 people, planned
Started
4 Feb 2023
Planned end
28 Feb 2025
Type of study
Interventional
Record updated
21 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with signs that suggest cardiac amyloidosis (a heart disease caused by protein build-up). It tests whether a PET-CT scan with 18F-florbetaben can diagnose cardiac AL amyloidosis without invasive tests.

Age
Older than 18 years
Sex
Men and women
Disease stage
Signs that doctors judge compatible with cardiac amyloidosis: raised NT-proBNP (>332 ng/L, without kidney failure or atrial fibrillation) or BNP >81 ng/L, or a thick heart wall (>12 mm on echocardiogram), or a typical pattern on heart MRI.
Earlier treatment
Must not have joined a trial with an experimental drug within 30 days before screening or 5 half-lives of the study drug, whichever is longer.

Main reasons for not taking part

  • Allergy to the active substance or an ingredient of Neuraceq
  • Chronic kidney disease (eGFR <30 mL/min/1,73 m2)
  • Liver disease with raised liver tests
  • Pregnancy or breastfeeding
  • Cannot lie flat for about 60 minutes

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Men and women aged >18 years
  • Ability to understand, sign and date the informed consent
  • NT-proBNP values >332 ng/L in the absence of renal insufficiency or atrial fibrillation or left ventricular mean wall thickness >12 mm on echocardiogram and/or a pattern of circumferential or diffuse subendocardial late gadolinium enhancement and/or BNP >81 ng/L, in a clinical setting judged compatible with CA by experienced clinicians

Who cannot take part

  • Participation to a study involving the administration of an experimental drug within 30 days from the screening or 5 half-lives of the study drug, whichever the longest
  • Hypersensitivity to the active principle or any excipient listed in the paragraph 6.1 of the Summary of Product Characteristics (RCP) of Neuraceq®
  • Chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1,73 m2)
  • New York Heart Association (NYHA) class IV
  • Liver disease [elevation >2 times above the upper reference limit of AST (normal range: males 34 UI/L, females 30 UI/ L), ALT (normal range: males 40 UI/L, females 35 UI/L), gamma-GT (normal range: 64 UI/L)
  • Pregnancy or breastfeeding, women with childbearing potential and sexually active not employing highly effective contraceptive methods with a low dependency on the user (from the screening to the end of visit 1), which include: i. abstinence, ii. sexual intercourse only with same-sex partners, iii. monogamous relationship with a partner with prior vasectomy, iv. intrauterine device, v. combined hormonal contraception including estrogens and progesteron-like hormones plus the inhibition of ovulation (oral, intravaginal or transdermal), vi. hormonal contraception based on progesterone- like compounds plus the inhibition of ovulation (oral, injectable, implantable), viii. intrauterine device with hormone release. The highly effective contraceptive measures above are not required for women made sterile by surgical means (for example through tube ligation, hysterectomy, bilateral salpingectomy, bilateral ovariectomy) or after the menopause, defined as 12 months of spontaneous amenorrhea without another clinical cause and with elevated FSH levels in agreement with the expected values for the menopause. For patients with true abstinence or with just same-sex partners, contraception is not required, as far as this is in line with their preferred and habitual lifestyle. Periodical abstinence (for example, estimate of the timing of ovulation or assessment of body temperature) and coitus interruptus are not acceptable contraceptive methods. If a patient stops to be abstinent, she must use the highly effective contraceptive methods above. The pregnancy status in women potentially fertile will be checked through the measurement of beta human gonadotropin on the serum and repeated at the end of the study
  • Performing a PET/CT or scintigraphic exam within 24 hours
  • Impossibility to lay flat for about 60 minutes
  • Lack of informed consent or impossibility to complete study procedures

Where in Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIIIBergamo, ItalyTaking people
  • University Hospital Of FerraraFerrara, ItalyTaking people
  • Azienda Ospedaliera dei ColliNaples, ItalyTaking people
  • Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
  • Fondazione Toscana Gabriele MonasterioPisa, ItalyTaking people
  • Azienda Sanitaria Universitaria Giuliano IsontinaTrieste, ItalyTaking people

About the trial

What the trial wants to find out

To define the concordance (with 95% confidence interval) of two pathways for the diagnosis of AL-CA in patients with a monoclonal component: the traditional (invasive) pathway and a non-invasive pathway using PET/CT with 18F-florbetaben ( visual assessment)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) to non-invasively diagnose cardiac AL amyloidosis: the PETAL study.
Plain-language title
Tests a PET scan to find heart amyloidosis without a biopsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 January 2025